national stem-cell therapy logo

BioCardia Unveils Groundbreaking Results in Phase III CardiAMP Cell Therapy for Heart Failure

Help Spread The Word, Share Post:

BioCardia, Inc., a leader in biotechnological advancements for cardiovascular diseases, recently announced remarkable interim results from its Phase III CardiAMP® Cell Therapy trial for treating advanced chronic heart failure.

These findings mark a significant milestone in the pursuit of innovative treatments for heart failure, showcasing the potential of stem cell therapy to revolutionize patient care.

A Leap Forward in Heart Failure Treatment

The CardiAMP Cell Therapy trial focused on patients with advanced chronic heart failure, revealing a notable 37% relative risk reduction in heart death equivalents and a 9% reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at a mean follow-up of 20 months.

These results were even more pronounced in a large subgroup of patients with elevated NTproBNP, a biomarker indicating heart distress, who experienced an astounding 86% reduction in heart death equivalents and a 24% reduction in non-fatal MACCE.

Spotlight on Elevated NTproBNP Patients

The subgroup with elevated NTproBNP, constituting 59% of the trial’s participants, showcased the profound impact of CardiAMP cell therapy.

This group saw a significant decrease in heart death equivalents, suggesting a particularly beneficial effect of the therapy on patients with this biomarker of heart failure.

FDA-Approved Follow-On Trial

Encouraged by these positive interim results, BioCardia has initiated a follow-on Phase III trial (CardiAMP HF II) specifically targeting the high-responding patient population with elevated NTproBNP. This step aims to further validate the promising outcomes observed in the interim analysis.

The Potential of CardiAMP Cell Therapy

The CardiAMP Cell Therapy employs a patient’s own stem cells in a minimally invasive procedure to potentially stimulate the body’s natural healing mechanisms.

This innovative approach has demonstrated not only a reduction in heart death equivalents and MACCE but also trends toward improved heart function and reduced ventricular tachyarrhythmias.

A Glimpse into the Future with CardiALLO™

In addition to the CardiAMP trial, BioCardia reported the commencement of a Phase I/II study for its CardiALLO™ allogeneic mesenchymal stem cell therapy. This “off the shelf” therapy represents another frontier in treating heart failure, emphasizing the company’s commitment to exploring stem cell solutions for cardiovascular diseases.


BioCardia’s interim results from the Phase III CardiAMP Cell Therapy trial represent a beacon of hope for patients with advanced chronic heart failure, especially those with elevated NTproBNP.

As the medical community eagerly awaits the final analysis and results of the follow-on trial, there is a growing sense of optimism that stem cell therapy may soon offer a transformative treatment option for heart failure, potentially improving outcomes and quality of life for millions of patients worldwide.

More info:

*** All content on is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

Stay Connected

More Updates